Stemline Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-08-01
- Employees
- 100
- Market Cap
- -
- Website
- http://www.stemline.com
Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06638307
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
- Conditions
- Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Stemline Therapeutics Inc.
- Target Recruit Count
- 1972
- Registration Number
- 2024-515445-42-00
- Locations
- 🇺🇸
Southern Cancer Center, PC, Daphne, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06456463
- Locations
- 🇺🇸
Fred Hutch Cancer Center, Seattle, Washington, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06126575
- Locations
- 🇺🇸
Inland Empire Clinical Trials, LLC, Yucaipa, California, United States
🇺🇸Floridian Clinical Research, Miami, Florida, United States
🇺🇸American Research Corp, San Antonio, Texas, United States
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05596409
- Locations
- 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇺🇸OPN Healthcare, Arcadia, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- Next